Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Safety of Istradefylline in Parkinson's Disease
NCT00199381Phase 3Terminated
- Sponsor
- Kyowa Kirin
- Start
- Oct 2005
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Istradefylline in Parkinson's disease (PD), sponsored by Kyowa Kirin. Primary endpoint: Safety as Measured by Adverse Events at 32 months. Started Oct 2005; status: terminated.
02
Drugs
Istradefylline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00199381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199381.